MULTICENTRE, OPEN LABEL, RANDOMIZED, TWO-ARM, PARALLEL-GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF ENVARSUS COMPARED WITH TACROLIMUS USED AS PER CURRENT CLINICAL PRACTICE IN THE INITIAL MAINTENANCE SETTING IN DE NOVO KIDNEY TRANSPLANT PATIENTS.
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2018
At a glance
- Drugs Tacrolimus (Primary) ; Tacrolimus; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms STEADY study
- Sponsors Chiesi Farmaceutici
- 06 Jun 2018 Primary endpoint has been met. (Tacrolimus total daily dose (TDD)) as per result presented at the 2018 American Transplant Congress
- 06 Jun 2018 Results presented at the 2018 American Transplant Congress
- 10 Mar 2017 This trial has been completed in Austria - (end date: 2017-01-24).